Share Price and Basic Stock Data
Last Updated: December 26, 2025, 11:05 pm
| PEG Ratio | -7.32 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Concord Drugs Ltd operates within the pharmaceuticals sector, focusing on the production and distribution of pharmaceutical products. As of the latest data, the company reported a market capitalization of ₹84.4 Cr and a stock price of ₹84.4. The revenue trends indicate fluctuations in sales over recent quarters, with sales recorded at ₹12.53 Cr in June 2022, peaking at ₹14.47 Cr in March 2024 before declining to ₹7.38 Cr in September 2023. The trailing twelve months (TTM) sales stood at ₹42.18 Cr, showcasing a downward trend compared to the ₹51.31 Cr reported in March 2023. This decline reflects a challenging operating environment, with a significant drop in sales in the first half of FY 2024. The company’s ability to navigate these fluctuations will be critical in maintaining its market position and meeting operational expenses, which averaged ₹39.58 Cr in FY 2024.
Profitability and Efficiency Metrics
Concord Drugs Ltd reported a net profit of ₹0.53 Cr, translating to a low P/E ratio of 159, indicating investor skepticism regarding future earnings growth. The company’s operating profit margin (OPM) stood at 7.03%, with the highest recorded OPM of 20.73% in September 2023, suggesting periods of strong operational efficiency. However, this is counterbalanced by low return on equity (ROE) at 0.88% and return on capital employed (ROCE) at 4.73%, both of which are below industry averages. The interest coverage ratio (ICR) at 2.05x indicates that the company can meet its interest obligations, albeit with limited capacity for additional debt. The cash conversion cycle (CCC) of 332.82 days highlights inefficiencies in inventory management and receivables collection, which could strain liquidity if not addressed promptly.
Balance Sheet Strength and Financial Ratios
Concord Drugs Ltd’s balance sheet reflects a reserve of ₹24.42 Cr against borrowings of ₹14.89 Cr, establishing a reasonable cushion for financial stability. The equity capital has increased to ₹10.00 Cr in FY 2025, while total liabilities stood at ₹58.58 Cr, indicating that the company is maintaining a manageable debt level with a total debt-to-equity ratio of 0.50. The current ratio of 1.56 suggests that the company is in a position to cover its short-term liabilities, though the quick ratio of 0.59 indicates potential liquidity issues. Financial ratios such as the return on assets (ROA) at 0.51% and net profit margin at 0.74% are lower compared to sector norms, reflecting challenges in effectively utilizing assets and generating profit. The price-to-book value (P/BV) ratio of 0.91x further indicates that the stock is trading below its book value, potentially signaling undervaluation or operational concerns.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Concord Drugs Ltd reveals a significant promoter holding of 54.39%, reflecting strong insider confidence in the company’s direction. The public ownership stood at 45.61%, with a notable increase in the number of shareholders to 4,718 as of the latest report. This growing base of shareholders could indicate an increasing interest in the company, despite recent performance challenges. The gradual rise in promoter shareholding from 49% in December 2022 to the current level suggests that insiders are confident in the company’s future prospects. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may raise concerns regarding broader market confidence. The reliance on public investment could lead to volatility, particularly in reaction to financial performance fluctuations.
Outlook, Risks, and Final Insight
Looking forward, Concord Drugs Ltd faces both opportunities and challenges. The company’s ability to stabilize sales and improve profitability metrics will be critical. Potential risks include continued fluctuations in revenue, which could hinder operational efficiency and investor confidence. Additionally, the high cash conversion cycle could strain liquidity, necessitating strategic improvements in inventory and receivables management. On the positive side, the substantial promoter holding suggests a commitment to long-term growth, which could attract further investor interest if performance improves. The company may benefit from focusing on cost control and enhancing operational efficiencies to return to growth. Overall, while there are promising elements, the path to recovery will require diligent management of operational challenges and market dynamics.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,816 Cr. | 443 | 479/192 | 99.7 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,100.18 Cr | 1,149.90 | 52.73 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.53 | 13.72 | 13.53 | 11.54 | 8.79 | 7.38 | 12.62 | 14.47 | 6.35 | 11.84 | 10.77 | 7.96 | 13.38 |
| Expenses | 11.56 | 12.53 | 12.08 | 10.80 | 7.39 | 5.85 | 12.06 | 14.28 | 5.62 | 11.05 | 9.45 | 7.03 | 12.44 |
| Operating Profit | 0.97 | 1.19 | 1.45 | 0.74 | 1.40 | 1.53 | 0.56 | 0.19 | 0.73 | 0.79 | 1.32 | 0.93 | 0.94 |
| OPM % | 7.74% | 8.67% | 10.72% | 6.41% | 15.93% | 20.73% | 4.44% | 1.31% | 11.50% | 6.67% | 12.26% | 11.68% | 7.03% |
| Other Income | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest | 0.34 | 0.42 | 0.45 | 0.42 | 0.39 | 0.39 | 0.43 | 0.38 | 0.37 | 0.39 | 0.43 | 0.53 | 0.42 |
| Depreciation | 0.39 | 0.53 | 0.38 | 0.31 | 0.38 | 0.38 | 0.38 | 0.39 | 0.34 | 0.34 | 0.37 | 0.37 | 0.37 |
| Profit before tax | 0.25 | 0.24 | 0.62 | 0.01 | 0.63 | 0.77 | -0.25 | -0.58 | 0.02 | 0.07 | 0.52 | 0.03 | 0.15 |
| Tax % | 28.00% | 25.00% | 25.81% | -600.00% | 23.81% | 31.17% | -4.00% | -39.66% | 50.00% | 28.57% | 57.69% | 33.33% | 26.67% |
| Net Profit | 0.19 | 0.18 | 0.45 | 0.07 | 0.49 | 0.53 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 |
| EPS in Rs | 0.22 | 0.21 | 0.51 | 0.08 | 0.53 | 0.57 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 |
Last Updated: August 19, 2025, 8:50 pm
Below is a detailed analysis of the quarterly data for Concord Drugs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 13.38 Cr.. The value appears strong and on an upward trend. It has increased from 7.96 Cr. (Mar 2025) to 13.38 Cr., marking an increase of 5.42 Cr..
- For Expenses, as of Jun 2025, the value is 12.44 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.03 Cr. (Mar 2025) to 12.44 Cr., marking an increase of 5.41 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.94 Cr.. The value appears strong and on an upward trend. It has increased from 0.93 Cr. (Mar 2025) to 0.94 Cr., marking an increase of 0.01 Cr..
- For OPM %, as of Jun 2025, the value is 7.03%. The value appears to be declining and may need further review. It has decreased from 11.68% (Mar 2025) to 7.03%, marking a decrease of 4.65%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.42 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.53 Cr. (Mar 2025) to 0.42 Cr., marking a decrease of 0.11 Cr..
- For Depreciation, as of Jun 2025, the value is 0.37 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.37 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.15 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Mar 2025) to 0.15 Cr., marking an increase of 0.12 Cr..
- For Tax %, as of Jun 2025, the value is 26.67%. The value appears to be improving (decreasing) as expected. It has decreased from 33.33% (Mar 2025) to 26.67%, marking a decrease of 6.66%.
- For Net Profit, as of Jun 2025, the value is 0.11 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Mar 2025) to 0.11 Cr., marking an increase of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.11. The value appears strong and on an upward trend. It has increased from 0.01 (Mar 2025) to 0.11, marking an increase of 0.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:55 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.95 | 40.02 | 50.68 | 57.43 | 51.80 | 48.08 | 51.34 | 51.33 | 58.96 | 51.31 | 43.26 | 36.93 | 42.18 |
| Expenses | 30.72 | 32.99 | 42.38 | 51.93 | 47.02 | 44.43 | 48.00 | 48.11 | 53.37 | 46.97 | 39.58 | 33.16 | 37.98 |
| Operating Profit | 3.23 | 7.03 | 8.30 | 5.50 | 4.78 | 3.65 | 3.34 | 3.22 | 5.59 | 4.34 | 3.68 | 3.77 | 4.20 |
| OPM % | 9.51% | 17.57% | 16.38% | 9.58% | 9.23% | 7.59% | 6.51% | 6.27% | 9.48% | 8.46% | 8.51% | 10.21% | 9.96% |
| Other Income | 0.12 | 0.37 | 0.15 | 0.09 | 0.14 | 0.09 | 0.12 | 3.86 | 0.10 | 0.01 | 0.01 | 0.01 | 0.00 |
| Interest | 1.78 | 2.72 | 2.57 | 2.36 | 1.88 | 1.59 | 1.54 | 1.42 | 1.68 | 1.62 | 1.59 | 1.72 | 1.78 |
| Depreciation | 1.14 | 3.63 | 2.91 | 2.58 | 2.40 | 1.71 | 1.46 | 1.37 | 1.76 | 1.60 | 1.54 | 1.42 | 1.45 |
| Profit before tax | 0.43 | 1.05 | 2.97 | 0.65 | 0.64 | 0.44 | 0.46 | 4.29 | 2.25 | 1.13 | 0.56 | 0.64 | 0.97 |
| Tax % | 20.93% | 33.33% | 40.74% | 73.85% | 50.00% | 9.09% | 28.26% | 23.54% | 28.89% | 21.24% | 25.00% | 54.69% | |
| Net Profit | 0.34 | 0.70 | 1.75 | 0.16 | 0.32 | 0.41 | 0.33 | 3.28 | 1.59 | 0.89 | 0.42 | 0.30 | 0.53 |
| EPS in Rs | 0.47 | 0.97 | 2.42 | 0.22 | 0.41 | 0.52 | 0.38 | 3.75 | 1.82 | 0.96 | 0.42 | 0.30 | 0.53 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 105.88% | 150.00% | -90.86% | 100.00% | 28.12% | -19.51% | 893.94% | -51.52% | -44.03% | -52.81% | -28.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | 44.12% | -240.86% | 190.86% | -71.88% | -47.64% | 913.45% | -945.46% | 7.50% | -8.78% | 24.24% |
Concord Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -6% |
| 3 Years: | -14% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -2% |
| 3 Years: | -43% |
| TTM: | 880% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 29% |
| 3 Years: | 26% |
| 1 Year: | 70% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: December 10, 2025, 4:06 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.24 | 7.24 | 7.24 | 7.24 | 7.86 | 7.86 | 8.74 | 8.74 | 8.74 | 9.32 | 10.00 | 10.00 | 10.00 |
| Reserves | 7.33 | 6.07 | 7.82 | 11.75 | 11.46 | 15.29 | 14.74 | 18.02 | 19.62 | 22.38 | 23.82 | 24.11 | 24.42 |
| Borrowings | 17.31 | 21.27 | 19.99 | 15.43 | 13.62 | 9.83 | 9.57 | 12.97 | 16.43 | 15.63 | 14.93 | 16.91 | 14.89 |
| Other Liabilities | 12.80 | 19.63 | 17.44 | 21.11 | 73.48 | 49.79 | 24.96 | 10.15 | 11.66 | 9.31 | 7.55 | 7.56 | 12.87 |
| Total Liabilities | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 62.18 |
| Fixed Assets | 20.84 | 18.32 | 15.18 | 13.64 | 13.51 | 11.85 | 10.52 | 13.83 | 13.97 | 12.86 | 11.63 | 12.17 | 11.48 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 1.00 | 0.00 | 0.55 | 0.92 | 1.63 | 2.00 | 2.05 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | 1.62 | 1.62 | 1.62 |
| Other Assets | 23.84 | 35.89 | 37.31 | 41.89 | 92.91 | 70.63 | 46.49 | 36.05 | 41.93 | 41.44 | 41.42 | 42.79 | 47.03 |
| Total Assets | 44.68 | 54.21 | 52.49 | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.30 | 58.58 | 62.18 |
Below is a detailed analysis of the balance sheet data for Concord Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 24.42 Cr.. The value appears strong and on an upward trend. It has increased from 24.11 Cr. (Mar 2025) to 24.42 Cr., marking an increase of 0.31 Cr..
- For Borrowings, as of Sep 2025, the value is 14.89 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 16.91 Cr. (Mar 2025) to 14.89 Cr., marking a decrease of 2.02 Cr..
- For Other Liabilities, as of Sep 2025, the value is 12.87 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.56 Cr. (Mar 2025) to 12.87 Cr., marking an increase of 5.31 Cr..
- For Total Liabilities, as of Sep 2025, the value is 62.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 58.58 Cr. (Mar 2025) to 62.18 Cr., marking an increase of 3.60 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11.48 Cr.. The value appears to be declining and may need further review. It has decreased from 12.17 Cr. (Mar 2025) to 11.48 Cr., marking a decrease of 0.69 Cr..
- For CWIP, as of Sep 2025, the value is 2.05 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 2.05 Cr., marking an increase of 0.05 Cr..
- For Investments, as of Sep 2025, the value is 1.62 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.62 Cr..
- For Other Assets, as of Sep 2025, the value is 47.03 Cr.. The value appears strong and on an upward trend. It has increased from 42.79 Cr. (Mar 2025) to 47.03 Cr., marking an increase of 4.24 Cr..
- For Total Assets, as of Sep 2025, the value is 62.18 Cr.. The value appears strong and on an upward trend. It has increased from 58.58 Cr. (Mar 2025) to 62.18 Cr., marking an increase of 3.60 Cr..
Notably, the Reserves (24.42 Cr.) exceed the Borrowings (14.89 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -14.08 | -14.24 | -11.69 | -9.93 | -8.84 | -6.18 | -6.23 | -9.75 | -10.84 | -11.29 | -11.25 | -13.14 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 180.83 | 249.90 | 183.51 | 99.46 | 501.49 | 367.66 | 180.94 | 147.41 | 141.52 | 116.31 | 117.87 | 125.22 |
| Inventory Days | 65.28 | 65.82 | 76.39 | 87.31 | 156.96 | 171.81 | 140.84 | 100.83 | 151.64 | 156.25 | 202.72 | 252.62 |
| Days Payable | 140.64 | 207.64 | 92.05 | 129.50 | 559.47 | 393.02 | 109.72 | 26.76 | 62.25 | 45.98 | 35.17 | 45.03 |
| Cash Conversion Cycle | 105.47 | 108.09 | 167.85 | 57.27 | 98.98 | 146.44 | 212.05 | 221.48 | 230.90 | 226.58 | 285.41 | 332.82 |
| Working Capital Days | 55.48 | 68.04 | 113.14 | 4.00 | 79.27 | 102.33 | 103.37 | 140.30 | 112.48 | 145.12 | 126.56 | 134.22 |
| ROCE % | 7.15% | 11.35% | 16.06% | 8.67% | 7.48% | 6.16% | 6.06% | 5.36% | 9.30% | 5.97% | 4.48% | 4.73% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.34 | 0.47 | 1.06 |
| Diluted EPS (Rs.) | 0.34 | 0.47 | 1.06 |
| Cash EPS (Rs.) | 1.77 | 2.03 | 2.80 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 34.11 | 33.82 | 34.03 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 34.11 | 33.82 | 34.03 |
| Revenue From Operations / Share (Rs.) | 45.24 | 44.92 | 55.91 |
| PBDIT / Share (Rs.) | 4.15 | 4.05 | 4.92 |
| PBIT / Share (Rs.) | 2.72 | 2.50 | 3.17 |
| PBT / Share (Rs.) | 0.69 | 0.62 | 1.34 |
| Net Profit / Share (Rs.) | 0.33 | 0.47 | 1.06 |
| NP After MI And SOA / Share (Rs.) | 0.33 | 0.47 | 1.06 |
| PBDIT Margin (%) | 9.16 | 9.01 | 8.79 |
| PBIT Margin (%) | 6.00 | 5.55 | 5.67 |
| PBT Margin (%) | 1.52 | 1.40 | 2.39 |
| Net Profit Margin (%) | 0.74 | 1.05 | 1.89 |
| NP After MI And SOA Margin (%) | 0.74 | 1.05 | 1.89 |
| Return on Networth / Equity (%) | 0.98 | 1.39 | 3.10 |
| Return on Capital Employeed (%) | 6.97 | 6.66 | 8.07 |
| Return On Assets (%) | 0.51 | 0.80 | 1.69 |
| Long Term Debt / Equity (X) | 0.03 | 0.01 | 0.06 |
| Total Debt / Equity (X) | 0.50 | 0.49 | 0.50 |
| Asset Turnover Ratio (%) | 0.73 | 0.76 | 0.00 |
| Current Ratio (X) | 1.56 | 2.09 | 2.01 |
| Quick Ratio (X) | 0.59 | 1.02 | 1.08 |
| Inventory Turnover Ratio (X) | 1.88 | 2.09 | 0.00 |
| Interest Coverage Ratio (X) | 2.05 | 2.17 | 2.68 |
| Interest Coverage Ratio (Post Tax) (X) | 1.17 | 1.25 | 1.58 |
| Enterprise Value (Cr.) | 48.05 | 51.59 | 41.61 |
| EV / Net Operating Revenue (X) | 1.06 | 1.15 | 0.79 |
| EV / EBITDA (X) | 11.58 | 12.73 | 9.08 |
| MarketCap / Net Operating Revenue (X) | 0.68 | 0.78 | 0.49 |
| Price / BV (X) | 0.91 | 1.04 | 0.80 |
| Price / Net Operating Revenue (X) | 0.68 | 0.78 | 0.49 |
| EarningsYield | 0.01 | 0.01 | 0.03 |
After reviewing the key financial ratios for Concord Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.47 (Mar 24) to 0.34, marking a decrease of 0.13.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has decreased from 0.47 (Mar 24) to 0.34, marking a decrease of 0.13.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.77. This value is below the healthy minimum of 3. It has decreased from 2.03 (Mar 24) to 1.77, marking a decrease of 0.26.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 34.11. It has increased from 33.82 (Mar 24) to 34.11, marking an increase of 0.29.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 34.11. It has increased from 33.82 (Mar 24) to 34.11, marking an increase of 0.29.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 45.24. It has increased from 44.92 (Mar 24) to 45.24, marking an increase of 0.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 4.15. This value is within the healthy range. It has increased from 4.05 (Mar 24) to 4.15, marking an increase of 0.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.72. This value is within the healthy range. It has increased from 2.50 (Mar 24) to 2.72, marking an increase of 0.22.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.69. This value is within the healthy range. It has increased from 0.62 (Mar 24) to 0.69, marking an increase of 0.07.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.47 (Mar 24) to 0.33, marking a decrease of 0.14.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.47 (Mar 24) to 0.33, marking a decrease of 0.14.
- For PBDIT Margin (%), as of Mar 25, the value is 9.16. This value is below the healthy minimum of 10. It has increased from 9.01 (Mar 24) to 9.16, marking an increase of 0.15.
- For PBIT Margin (%), as of Mar 25, the value is 6.00. This value is below the healthy minimum of 10. It has increased from 5.55 (Mar 24) to 6.00, marking an increase of 0.45.
- For PBT Margin (%), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 10. It has increased from 1.40 (Mar 24) to 1.52, marking an increase of 0.12.
- For Net Profit Margin (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has decreased from 1.05 (Mar 24) to 0.74, marking a decrease of 0.31.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 8. It has decreased from 1.05 (Mar 24) to 0.74, marking a decrease of 0.31.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 15. It has decreased from 1.39 (Mar 24) to 0.98, marking a decrease of 0.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.97. This value is below the healthy minimum of 10. It has increased from 6.66 (Mar 24) to 6.97, marking an increase of 0.31.
- For Return On Assets (%), as of Mar 25, the value is 0.51. This value is below the healthy minimum of 5. It has decreased from 0.80 (Mar 24) to 0.51, marking a decrease of 0.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.50. This value is within the healthy range. It has increased from 0.49 (Mar 24) to 0.50, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.73. It has decreased from 0.76 (Mar 24) to 0.73, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.09 (Mar 24) to 1.56, marking a decrease of 0.53.
- For Quick Ratio (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.59, marking a decrease of 0.43.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.88. This value is below the healthy minimum of 4. It has decreased from 2.09 (Mar 24) to 1.88, marking a decrease of 0.21.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.05. This value is below the healthy minimum of 3. It has decreased from 2.17 (Mar 24) to 2.05, marking a decrease of 0.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 3. It has decreased from 1.25 (Mar 24) to 1.17, marking a decrease of 0.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 48.05. It has decreased from 51.59 (Mar 24) to 48.05, marking a decrease of 3.54.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.15 (Mar 24) to 1.06, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 11.58. This value is within the healthy range. It has decreased from 12.73 (Mar 24) to 11.58, marking a decrease of 1.15.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.68, marking a decrease of 0.10.
- For Price / BV (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.04 (Mar 24) to 0.91, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.68, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Concord Drugs Ltd:
- Net Profit Margin: 0.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.97% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.98% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.17
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.59
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 160 (Industry average Stock P/E: 52.73)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.5
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Survey No.249, R R District Telangana 501511 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Nagi Reddy | Chairman & Managing Director |
| Mr. S Manoj Kumar Reddy | Whole Time Director |
| Mr. S Koni Reddy | WholeTime Director & CFO |
| Mr. K Ramachandra Reddy | Independent Director |
| Ms. Sumeela Kasu | Independent Director |
| Mr. S Nagavenkata Hareesh | Independent Director |
FAQ
What is the intrinsic value of Concord Drugs Ltd?
Concord Drugs Ltd's intrinsic value (as of 26 December 2025) is 39.52 which is 53.51% lower the current market price of 85.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 85.0 Cr. market cap, FY2025-2026 high/low of 92.5/26.1, reserves of ₹24.42 Cr, and liabilities of 62.18 Cr.
What is the Market Cap of Concord Drugs Ltd?
The Market Cap of Concord Drugs Ltd is 85.0 Cr..
What is the current Stock Price of Concord Drugs Ltd as on 26 December 2025?
The current stock price of Concord Drugs Ltd as on 26 December 2025 is 85.0.
What is the High / Low of Concord Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Concord Drugs Ltd stocks is 92.5/26.1.
What is the Stock P/E of Concord Drugs Ltd?
The Stock P/E of Concord Drugs Ltd is 160.
What is the Book Value of Concord Drugs Ltd?
The Book Value of Concord Drugs Ltd is 34.4.
What is the Dividend Yield of Concord Drugs Ltd?
The Dividend Yield of Concord Drugs Ltd is 0.00 %.
What is the ROCE of Concord Drugs Ltd?
The ROCE of Concord Drugs Ltd is 4.73 %.
What is the ROE of Concord Drugs Ltd?
The ROE of Concord Drugs Ltd is 0.88 %.
What is the Face Value of Concord Drugs Ltd?
The Face Value of Concord Drugs Ltd is 10.0.